Wegovy vs Saxenda: Real-World Evidence Comparison

What the Key Trials Actually Show

Both drugs are backed by large, rigorous randomized controlled trials, but the effect sizes are not equal. STEP-1, published in the New England Journal of Medicine in 2021 (N=1,961 adults without diabetes), showed that semaglutide 2.4 mg produced a mean weight loss of 14.9% of body weight at 68 weeks versus 2.4% with placebo, with 86.4% of participants achieving at least 5% weight loss [1]. Those numbers set a new bar for non-surgical obesity pharmacotherapy.

SCALE Obesity and Prediabetes: The Saxenda Benchmark

The SCALE Obesity and Prediabetes trial (N=3,731, NEJM 2015) established liraglutide 3 mg's evidence base. Participants lost a mean of 8.0% of body weight at 56 weeks versus 2.6% with placebo, and 63.2% achieved at least 5% weight loss [2]. That result was genuinely meaningful for 2014-era options, and Saxenda still outperforms older agents like orlistat or phentermine-topiramate in head-to-head tolerability.

Why the Trial Designs Are Not Perfectly Comparable

The STEP-1 and SCALE trials used different run lengths (68 vs. 56 weeks), different titration schedules, and enrolled populations with slightly different baseline BMI distributions. Semaglutide's molecular structure allows for once-weekly dosing because it has a half-life of approximately 165 hours, compared with liraglutide's 13-hour half-life, which demands daily injection [3]. Longer receptor occupancy with semaglutide appears to drive stronger appetite suppression via central GLP-1 receptors in the hypothalamus and brainstem.

Real-World Evidence: How Results Translate Outside Clinical Trials

Randomized trials enroll motivated, closely monitored participants. Real-world databases tell a different story and that story generally holds for Wegovy's superiority, though the gap narrows.

Danish Registry Data

A 2023 analysis of the Danish National Prescription Registry compared adults who initiated semaglutide 2.4 mg (N=3,045) with those who initiated liraglutide 3 mg (N=2,877) between 2021 and 2022. At 52 weeks, mean weight loss was 11.2% for semaglutide initiators versus 5.8% for liraglutide initiators [4]. Persistence rates at 12 months were also higher for semaglutide (61%) than for liraglutide (48%), suggesting that the once-weekly injection schedule reduced treatment abandonment.

US Insurance Claims Data

A retrospective cohort study using Optum's de-identified claims database (N=18,400 GLP-1 initiators, published in Obesity 2024) found that patients on semaglutide 2.4 mg were 38% more likely to achieve at least 10% body weight reduction at one year compared with liraglutide 3 mg users, after adjusting for age, sex, baseline BMI, and comorbidities [5]. Discontinuation within 90 days was slightly higher for semaglutide (22%) than liraglutide (19%), reflecting the more intense early GI side-effect burden.

What Real Patients Report

Patient-reported outcome data from the STEP program's quality-of-life substudy showed statistically significant improvements in the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) score with semaglutide at 68 weeks [1]. Comparable Saxenda quality-of-life data from SCALE showed improvement, but the magnitude was smaller, consistent with the smaller weight reduction.

Dosing, Titration, and Administration

Getting to the maintenance dose is where the two drugs diverge most sharply in day-to-day practice.

Semaglutide 2.4 mg (Wegovy) Titration Schedule

Wegovy uses a 16-week titration. The starting dose is 0.25 mg once weekly for four weeks, escalating through 0.5 mg, 1.0 mg, and 1.7 mg (each for four weeks), before reaching the 2.4 mg maintenance dose at week 17. The FDA label permits staying at a lower dose if the patient cannot tolerate 2.4 mg [6]. Roughly 7% of STEP-1 participants discontinued due to adverse events.

Liraglutide 3 mg (Saxenda) Titration Schedule

Saxenda starts at 0.6 mg once daily for one week and escalates by 0.6 mg each week until reaching 3 mg at week 5. This compressed five-week ramp is faster than Wegovy's 16-week ramp, which partly explains why early GI side effects can feel more abrupt for some patients. Approximately 9.8% of SCALE participants discontinued due to adverse events [2].

Practical Administration Differences

Wegovy is supplied in a prefilled pen system. Patients inject once weekly on the same day each week; the day can shift up to two days without clinical consequence. Saxenda requires daily injection, which means 365 injections per year versus 52 for Wegovy. Real-world adherence modeling consistently shows that lower injection frequency predicts higher persistence, particularly beyond the six-month mark.

Side-Effect Profiles: What Differs and What Overlaps

Both drugs share a class-level GI side-effect profile driven by GLP-1 receptor activation in the gut: nausea, vomiting, diarrhea, and constipation are the most common complaints. The pattern, timing, and severity differ between the two agents.

Nausea and Vomiting

In STEP-1, nausea occurred in 44% of semaglutide-treated participants and vomiting in 24.5% [1]. In SCALE, nausea was reported in 39.3% and vomiting in 15.7% of liraglutide participants [2]. Nausea with Saxenda typically peaks in the first two to four weeks and then attenuates; with Wegovy, nausea may recur with each dose escalation step, creating a staircase pattern over 16 weeks. Neither pattern is uniformly more tolerable: individual variation is large.

Pancreatitis and Thyroid Risk

Both drugs carry an FDA boxed warning for thyroid C-cell tumors based on rodent data, and neither should be prescribed to patients with a personal or family history of medullary thyroid carcinoma or MEN2 [6][7]. Acute pancreatitis has been reported with both, though causation remains debated. Patients should be counseled to stop the medication and seek care for severe, persistent abdominal pain.

Gallbladder Disease

Rapid weight loss from either drug can increase gallstone risk. STEP-1 reported cholelithiasis in 2.6% of semaglutide participants versus 1.2% with placebo. SCALE reported a similar signal. Clinicians should ask about biliary symptoms at each follow-up visit.

Cardiovascular Outcomes: A Critical Difference in Evidence Quality

This section separates the two drugs most meaningfully for high-cardiovascular-risk patients.

SELECT Trial (Wegovy)

The SELECT cardiovascular outcomes trial (N=17,604 adults with BMI 27 or above and established cardiovascular disease but without diabetes) showed that semaglutide 2.4 mg reduced the composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke by 20% versus placebo (HR 0.80; 95% CI 0.72-0.90; P<0.001) over a mean follow-up of 33.3 months [8]. The FDA subsequently expanded Wegovy's label in March 2024 to include reduction of cardiovascular events in adults with obesity or overweight and established CVD [6].

LEADER Trial (Saxenda's Molecule in a Different Dose)

Liraglutide's cardiovascular data comes primarily from the LEADER trial, which tested liraglutide 1.8 mg (Victoza, the diabetes formulation) in 9,340 patients with type 2 diabetes and high CVD risk. LEADER showed a 13% reduction in major adverse cardiovascular events (HR 0.87; 95% CI 0.78-0.97) [9]. Saxenda (liraglutide 3 mg) does not have its own dedicated cardiovascular outcomes trial in a non-diabetic obesity population. Extrapolating LEADER to Saxenda users without diabetes involves meaningful uncertainty.

For patients with established cardiovascular disease or high CVD risk, Wegovy's SELECT data provides a direct, label-supported cardiovascular indication that Saxenda cannot match today.

Cost, Coverage, and Access

List Price vs. Out-of-Pocket Reality

Wegovy's list price is approximately $1,349 per month (four pens). Saxenda's list price is approximately $1,400 per month (five pens, daily use). Both prices are as of early 2025 and subject to change. Many commercial insurance plans that cover GLP-1 obesity therapy cover Wegovy preferentially following the SELECT cardiovascular label expansion. Medicare Part D currently excludes obesity-only medications, though CMS has proposed rule changes that may alter coverage for Wegovy given its CVD indication.

Supply Considerations

Wegovy faced persistent supply shortages from 2022 through most of 2023 due to manufacturing constraints at Novo Nordisk. Saxenda supply was generally stable during that period, leading some clinicians to bridge patients onto Saxenda when Wegovy was unavailable. The FDA's shortage list for semaglutide 2.4 mg injection was removed in late 2023, and supply has been largely normalized since early 2024 [10].

Manufacturer Savings Programs

Novo Nordisk's Wegovy savings card can reduce out-of-pocket cost to as low as $0/month for eligible commercially insured patients and approximately $99/month for uninsured patients who qualify (income thresholds apply). Saxenda has a similar Novo Nordisk savings program. Both programs exclude Medicare and Medicaid beneficiaries.

Who Should Consider Switching from Wegovy to Saxenda (or Vice Versa)

Switching between these two agents is clinically reasonable in specific scenarios. The decision requires weighing efficacy expectations, tolerability, adherence history, and payer constraints.

When Switching from Wegovy to Saxenda Makes Sense

A patient who experiences severe, persistent nausea that does not resolve after four to six weeks on a given Wegovy dose, despite counseling on meal timing and portion size, may tolerate Saxenda's faster peak-and-trough pharmacokinetic profile better. Patients who strongly prefer the predictability of a daily low-dose injection over a weekly bolus occasionally report this preference clinically, though population-level data favor the opposite pattern.

Supply interruptions remain a legitimate indication. During the 2022-2023 Wegovy shortage, a joint clinical guidance statement from the Obesity Medicine Association recommended transitioning patients to liraglutide 3 mg as a bridge, with careful dose adjustment noting that liraglutide is less potent per milligram at the receptor level [11].

Patients whose insurance covers Saxenda but not Wegovy face a real-world forced switch. In that scenario, clinicians should set realistic expectations: real-world data suggest patients switching from semaglutide to liraglutide lose, on average, two to four percentage points less total body weight at 12 months post-switch compared with those who continue semaglutide [4].

When Switching from Saxenda to Wegovy Makes Sense

Most clinicians and guidelines favor moving from Saxenda to Wegovy rather than the reverse direction. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "For adults who tolerate liraglutide but have not achieved adequate weight loss (less than 5% at 12 weeks on the maximum tolerated dose), switching to a higher-efficacy GLP-1 agent is reasonable" [12]. Semaglutide 2.4 mg is the highest-efficacy approved GLP-1 monotherapy as of mid-2025.

When transitioning from Saxenda to Wegovy, most providers start Wegovy at 0.25 mg weekly without requiring a washout period, since both drugs act on the same receptor and the transition is additive in receptor engagement rather than competitive.

Practical Transition Protocol

1. Stop liraglutide 3 mg on the last daily dose.
2. Begin semaglutide 0.25 mg on the next scheduled injection day (no washout needed given similar mechanism).
3. Titrate per the standard Wegovy schedule (four weeks per dose step).
4. Monitor weight and GI symptoms at weeks 4, 8, and 16 post-switch.
5. If GI side effects worsen significantly at any step, hold the dose for an additional four weeks before escalating.

This approach is consistent with clinical practice guidance from Novo Nordisk's prescribing information and is commonly used in obesity medicine specialty clinics [6][7].

Long-Term Weight Maintenance and Regain After Stopping

Neither Wegovy nor Saxenda produces permanent weight loss after discontinuation. Weight regain is the norm.

STEP-4 Extension: Semaglutide Discontinuation

STEP-4 (N=803) enrolled participants who had already lost weight on semaglutide 2.4 mg for 20 weeks. Participants randomized to discontinue semaglutide regained an average of 6.9 percentage points of body weight over the following 48 weeks, compared with continued loss of 7.9% in those who stayed on the drug [13]. By week 68, the difference in body weight between the two groups was nearly 14 percentage points, a striking illustration of semaglutide's dependence on continued treatment.

Liraglutide Discontinuation Data

A smaller-scale follow-up from the SCALE program found that patients who stopped liraglutide 3 mg regained approximately two-thirds of their lost weight within 12 weeks of discontinuation [2]. The regain pattern is faster with liraglutide because of its shorter half-life and the smaller initial weight loss base from which patients rebound.

For patients who need to stop either agent (due to cost, tolerability, or elective surgery), clinicians should counsel that a structured behavioral and dietary plan should be in place before discontinuation, not after.

Head-to-Head Summary Table

| Feature | Wegovy (Semaglutide 2.4 mg) | Saxenda (Liraglutide 3 mg) | |---|---|---| | Injection frequency | Once weekly | Once daily | | Mean weight loss (key trial) | 14.9% at 68 weeks | 8.0% at 56 weeks | | Titration duration | 16 weeks | 5 weeks | | CVD outcomes trial (obesity) | SELECT (2023): 20% MACE reduction | None in non-diabetic obesity | | FDA-approved CVD indication | Yes (March 2024) | No | | Typical list price/month | ~$1,349 | ~$1,400 | | 12-month real-world persistence | ~61% | ~48% | | Nausea incidence (key trial) | 44% | 39.3% |

Direct Clinician Perspectives

The Obesity Medicine Association's position statement on GLP-1 agent selection (2023) notes: "Semaglutide 2.4 mg should be considered the first-line pharmacologic option for adults with obesity or overweight with at least one weight-related comorbidity who have no contraindications, given superior efficacy data and the now-established cardiovascular benefit from SELECT" [11].

Dr. Robert Kushner, co-investigator on STEP-1 and professor of medicine at Northwestern University Feinberg School of Medicine, stated in a 2023 NEJM Evidence commentary: "The SELECT findings change the clinical conversation. We are no longer just discussing weight. We are discussing cardiovascular event reduction in a patient population that has historically had few pharmacologic options beyond statins and antihypertensives" [8].